85 related articles for article (PubMed ID: 20100647)
1. Dual PET/CT with (18)F-DOPA and (18)F-FDG in metastatic medullary thyroid carcinoma and rapidly increasing calcitonin levels: Comparison with conventional imaging.
Marzola MC; Pelizzo MR; Ferdeghini M; Toniato A; Massaro A; Ambrosini V; Fanti S; Gross MD; Al-Nahhas A; Rubello D
Eur J Surg Oncol; 2010 Apr; 36(4):414-21. PubMed ID: 20100647
[TBL] [Abstract][Full Text] [Related]
2. Feasibility of
Hung WT; Liu CJ; Liu YL; Ko KY; Chou SW; Chang HH; Yang YL; Lu MY; Hsu WM
Pediatr Blood Cancer; 2024 Jul; 71(7):e30983. PubMed ID: 38605509
[TBL] [Abstract][Full Text] [Related]
3. Biological Evaluation of a Fluorescent-Imaging Agent for Medullary Thyroid Cancer in an Orthotopic Model.
Rossfeld KK; Justiniano SE; Ding H; Gong L; Kothandaraman S; Sawant D; Saji M; Wright CL; Kirschner LS; Ringel MD; Tweedle MF; Phay JE
J Clin Endocrinol Metab; 2017 Sep; 102(9):3268-3277. PubMed ID: 28591772
[TBL] [Abstract][Full Text] [Related]
4. Theranostics of Thyroid Cancer.
Giovanella L; Tuncel M; Aghaee A; Campenni A; Petranović Ovčariček P; De Virgilio A
Semin Nucl Med; 2024 Mar; ():. PubMed ID: 38503602
[TBL] [Abstract][Full Text] [Related]
5. Adult Neuroblastoma of the Neck Is Better Imaged With 18F-FDG PET/CT Than With 18F-DOPA PET/CT.
Alabed YZ
Clin Nucl Med; 2024 May; ():. PubMed ID: 38778475
[TBL] [Abstract][Full Text] [Related]
6. Hepatic Superscan in Medullary Thyroid Carcinoma: A Rare Presentation in [
Abdlkadir AS; Al-Adhami D; Alsyouf B; Alhouwari R; Al-Rasheed U; Jaber O; Mohamad I; Al-Ibraheem A
Nucl Med Mol Imaging; 2024 May; 58(3):147-149. PubMed ID: 38633289
[No Abstract] [Full Text] [Related]
7. Sensitivities evaluation of five radiopharmaceuticals in four common medullary thyroid carcinoma metastatic sites on PET/CT: a network meta-analysis and systematic review.
Li P; Zhang Y; Xu T; Zhu J; Wei T; Zhao W
Nucl Med Commun; 2023 Dec; 44(12):1114-1125. PubMed ID: 37769014
[TBL] [Abstract][Full Text] [Related]
8. Molecular imaging and related therapeutic options for medullary thyroid carcinoma: state of the art and future opportunities.
Imperiale A; Berti V; Burgy M; Cazzato RL; Piccardo A; Treglia G
Rev Endocr Metab Disord; 2024 Feb; 25(1):187-202. PubMed ID: 37715050
[TBL] [Abstract][Full Text] [Related]
9. Usefulness of PET-CT scan in recurrent thyroid cancer.
Dionigi G; Fama' F; Pignata SA; Pino A; Pontin A; Caruso E; Fu Y; Li S; Mazzeo C; Sun H; Baldari S
World J Otorhinolaryngol Head Neck Surg; 2020 Sep; 6(3):182-187. PubMed ID: 33073214
[TBL] [Abstract][Full Text] [Related]
10. The added diagnostic value of complementary gadoxetic acid-enhanced MRI to
Puhr-Westerheide D; Cyran CC; Sargsyan-Bergmann J; Todica A; Gildehaus FJ; Kunz WG; Stahl R; Spitzweg C; Ricke J; Kazmierczak PM
Cancer Imaging; 2019 Nov; 19(1):73. PubMed ID: 31727170
[TBL] [Abstract][Full Text] [Related]
11. EANM practice guideline for PET/CT imaging in medullary thyroid carcinoma.
Giovanella L; Treglia G; Iakovou I; Mihailovic J; Verburg FA; Luster M
Eur J Nucl Med Mol Imaging; 2020 Jan; 47(1):61-77. PubMed ID: 31482429
[TBL] [Abstract][Full Text] [Related]
12. Medullary Thyroid Carcinoma: An Update on Imaging.
Kushchayev SV; Kushchayeva YS; Tella SH; Glushko T; Pacak K; Teytelboym OM
J Thyroid Res; 2019; 2019():1893047. PubMed ID: 31360432
[TBL] [Abstract][Full Text] [Related]
13. Novel PET tracers: added value for endocrine disorders.
Bergeret S; Charbit J; Ansquer C; Bera G; Chanson P; Lussey-Lepoutre C
Endocrine; 2019 Apr; 64(1):14-30. PubMed ID: 30875057
[TBL] [Abstract][Full Text] [Related]
14. Positron Emission Tomography (PET) and PET/CT in Thyroid Cancer: A Systematic Review and Meta-Analysis.
Schütz F; Lautenschläger C; Lorenz K; Haerting J
Eur Thyroid J; 2018 Jan; 7(1):13-20. PubMed ID: 29594049
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic utility of PET/CT with
Romero-Lluch AR; Cuenca-Cuenca JI; Guerrero-Vázquez R; Martínez-Ortega AJ; Tirado-Hospital JL; Borrego-Dorado I; Navarro-González E
Eur J Nucl Med Mol Imaging; 2017 Nov; 44(12):2004-2013. PubMed ID: 28646462
[TBL] [Abstract][Full Text] [Related]
16. SPECT/CT and PET/CT molecular imaging in medullary thyroid carcinoma. Are we running in the right direction?
Maffione AM; Giammarile F; Rubello D
Eur J Nucl Med Mol Imaging; 2017 Sep; 44(10):1692-1694. PubMed ID: 28638977
[No Abstract] [Full Text] [Related]
17. (18)F-DOPA PET/CT in the diagnosis and localization of persistent medullary thyroid carcinoma.
Archier A; Heimburger C; Guerin C; Morange I; Palazzo FF; Henry JF; Schneegans O; Mundler O; Abdullah AE; Sebag F; Imperiale A; Taïeb D
Eur J Nucl Med Mol Imaging; 2016 Jun; 43(6):1027-33. PubMed ID: 26497699
[TBL] [Abstract][Full Text] [Related]
18. Depicting medullary thyroid cancer recurrence: the past and the future of nuclear medicine imaging.
Skoura E
Int J Endocrinol Metab; 2013 Oct; 11(4):e8156. PubMed ID: 24719630
[TBL] [Abstract][Full Text] [Related]
19. Normal biodistribution pattern and physiologic variants of 18F-DOPA PET imaging.
Chondrogiannis S; Marzola MC; Al-Nahhas A; Venkatanarayana TD; Mazza A; Opocher G; Rubello D
Nucl Med Commun; 2013 Dec; 34(12):1141-9. PubMed ID: 24128899
[TBL] [Abstract][Full Text] [Related]
20. 18F-fluorodihydroxyphenylalanine vs other radiopharmaceuticals for imaging neuroendocrine tumours according to their type.
Balogova S; Talbot JN; Nataf V; Michaud L; Huchet V; Kerrou K; Montravers F
Eur J Nucl Med Mol Imaging; 2013 Jun; 40(6):943-66. PubMed ID: 23417499
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
